论文部分内容阅读
总结艾塞那肽成功治疗2型糖尿病患者的临床特点。回顾分析33例艾塞那肽治疗的2型糖尿病患者临床资料和实验室检查,对治疗前后数据进行比较分析。经艾塞那肽4个月治疗后,患者空腹血糖(FPG),2 h餐后血糖(2h PG),糖化血红蛋白(Hb Alc)均明显降低;稳态模型指数HOMA-IR,肱动脉内皮依赖性舒张功能(FMD)和体重指数(BMI)显著下降;生化指标总胆固醇(TC),低密度脂蛋白(LDL-C),谷氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)显著下降。临床不良反应轻微。艾塞那肽治疗2型糖尿病患者,可以良好的控制血糖,减轻体重,改善胰岛素抵抗和脂质代谢紊乱。
To summarize the clinical features of exenatide in the treatment of type 2 diabetes. The clinical data and laboratory tests of 33 exenatide-treated type 2 diabetic patients were retrospectively analyzed. The data before and after treatment were compared and analyzed. Fasting plasma glucose (FPG), 2h postprandial plasma glucose (2h PG), and Hb Alc significantly decreased after exenatide treatment for 4 months. HOMA-IR, brachial artery endothelium dependent (FMD) and body mass index (BMI). The biochemical parameters TC, LDL-C, ALT and aspartate aminotransferase (AST) decreased significantly. Minor clinical adverse reactions. Exenatide in patients with type 2 diabetes, can control blood sugar, reduce weight, improve insulin resistance and lipid metabolism disorders.